{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:05Z","timestamp":1786979945302,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00280-017-3242-8","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T15:08:09Z","timestamp":1489763289000},"page":"661-671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["An apparent clinical pharmacokinetic drug\u2013drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism"],"prefix":"10.1007","volume":"79","author":[{"given":"Ka","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska Schaedeli","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Schlothauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Lahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Cosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Habben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eginhard","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland F.","family":"Staack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Krieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"3242_CR1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273\u2013286","journal-title":"Nat Rev Drug Discov"},{"key":"3242_CR2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"3242_CR3","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jvir.2010.08.009","volume":"21","author":"R Oklu","year":"2010","unstructured":"Oklu R, Walker TG, Wicky S, Hesketh R (2010) Angiogenesis and current antiangiogenic strategies for the treatment of cancer. J Vasc Interv Radiol 21:1791\u20131805","journal-title":"J Vasc Interv Radiol"},{"key":"3242_CR4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3322\/caac.20075","volume":"60","author":"KM Cook","year":"2010","unstructured":"Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222\u2013243","journal-title":"CA Cancer J Clin"},{"key":"3242_CR5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2004.05.020","volume":"213","author":"C-N Chen","year":"2004","unstructured":"Chen C-N, Hsieh F-J, Cheng Y-M et al (2004) The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 213:73\u201382","journal-title":"Cancer Lett"},{"key":"3242_CR6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0165-0378(03)00082-2","volume":"60","author":"W Yang","year":"2003","unstructured":"Yang W, Ahn H, Hinrichs M et al (2003) Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol 60:53\u201360","journal-title":"J Reprod Immunol"},{"key":"3242_CR7","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.2337\/diabetes.52.12.2959","volume":"52","author":"J Cai","year":"2003","unstructured":"Cai J, Ahmad S, Jiang WG et al (2003) Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 52:2959\u20132968","journal-title":"Diabetes"},{"key":"3242_CR8","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1538-7836.2003.00263.x","volume":"1","author":"M Autiero","year":"2003","unstructured":"Autiero M, Luttun A, Tjwa M, Carmeliet P (2003) Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1:1356\u20131370","journal-title":"J Thromb Haemost"},{"key":"3242_CR9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ijc.25492","volume":"128","author":"H-X Xu","year":"2011","unstructured":"Xu H-X, Zhu X-D, Zhuang P-Y et al (2011) Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer 128:1559\u20131569","journal-title":"Int J Cancer"},{"key":"3242_CR10","first-page":"239","volume":"6","author":"A Escudero-Esparza","year":"2009","unstructured":"Escudero-Esparza A, Martin TA, Davies ML, Jiang WG (2009) PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genom Proteom 6:239\u2013246","journal-title":"Cancer Genom Proteom"},{"key":"3242_CR11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.athoracsur.2009.04.038","volume":"88","author":"E Pompeo","year":"2009","unstructured":"Pompeo E, Albonici L, Doldo E et al (2009) Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann Thorac Surg 88:426\u2013431","journal-title":"Ann Thorac Surg"},{"key":"3242_CR12","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/hed.21335","volume":"32","author":"S-J Cheng","year":"2010","unstructured":"Cheng S-J, Lee J-J, Kok S-H et al (2010) Expression of placenta growth factor: an independent factor for prediction of progression and prognosis of oral cancer. Head Neck 32:1363\u20131369","journal-title":"Head Neck"},{"key":"3242_CR13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3393\/jksc.2012.28.6.315","volume":"28","author":"CY Sung","year":"2012","unstructured":"Sung CY, Son MW, Ahn TS et al (2012) Expression of placenta growth factor in colorectal carcinomas. J Korean Soc Coloproctol 28:315\u2013320","journal-title":"J Korean Soc Coloproctol"},{"key":"3242_CR14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.cell.2013.01.036","volume":"152","author":"M Snuderl","year":"2013","unstructured":"Snuderl M, Batista A, Kirkpatrick ND et al (2013) Targeting placental growth factor\/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152:1065\u20131076","journal-title":"Cell"},{"key":"3242_CR15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/bjc.2011.609","volume":"106","author":"U Lassen","year":"2012","unstructured":"Lassen U, Nielsen DL, S\u00f8rensen M et al (2012) A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Br J Cancer 106:678\u2013684","journal-title":"Br J Cancer"},{"key":"3242_CR16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","volume":"131","author":"C Fischer","year":"2007","unstructured":"Fischer C, Jonckx B, Mazzone M et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463\u2013475","journal-title":"Cell"},{"key":"3242_CR17","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.clinthera.2011.08.007","volume":"33","author":"T Martinsson-Niskanen","year":"2011","unstructured":"Martinsson-Niskanen T, Riisbro R, Larsson L et al (2011) Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin Ther 33:1142\u20131149","journal-title":"Clin Ther"},{"key":"3242_CR18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/neuonc\/nov019","volume":"17","author":"U Lassen","year":"2015","unstructured":"Lassen U, Chinot OL, McBain C, et al (2015) Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-Oncol 17:1007\u20131015","journal-title":"Neuro-Oncol"},{"key":"3242_CR19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","volume":"62","author":"J-F Lu","year":"2008","unstructured":"Lu J-F, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779\u2013786","journal-title":"Cancer Chemother Pharmacol"},{"key":"3242_CR20","volume-title":"Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Application","author":"J Gabrielsson","year":"2000","unstructured":"Gabrielsson J, Weiner D (2000) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Application, 3rd Ed, Swedish Pharmaceutical Press, Stockholm, Sweden","edition":"3"},{"issue":"2","key":"3242_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. doi: 10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"key":"3242_CR22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676","journal-title":"Nat Med"},{"key":"3242_CR23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493\u2013507","journal-title":"Clin Pharmacokinet"},{"key":"3242_CR24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548\u2013558","journal-title":"Clin Pharmacol Ther"},{"key":"3242_CR25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2125.2012.04172.x","volume":"74","author":"D Czock","year":"2012","unstructured":"Czock D, Keller F, Seidling HM (2012) Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Br J Clin Pharmacol 74:66\u201374","journal-title":"Br J Clin Pharmacol"},{"key":"3242_CR26","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1208\/s12248-014-9631-6","volume":"16","author":"K Han","year":"2014","unstructured":"Han K, Jin J, Maia M et al (2014) Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST Phase III trial. AAPS J 16:1056\u20131063","journal-title":"AAPS J"},{"key":"3242_CR27","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2:1097\u20131105","journal-title":"Genes Cancer"},{"key":"3242_CR28","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1038\/onc.2012.313","volume":"32","author":"B Li","year":"2013","unstructured":"Li B, Wang C, Zhang Y et al (2013) Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene 32:2952\u20132962","journal-title":"Oncogene"},{"key":"3242_CR29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3892\/or.2012.2178","volume":"29","author":"L Coenegrachts","year":"2012","unstructured":"Coenegrachts L, Schrauwen S, Van Bree R et al (2012) Increased expression of placental growth factor in high-grade endometrial carcinoma. Oncol Rep 29:413\u2013418","journal-title":"Oncol Rep"},{"key":"3242_CR30","first-page":"2381","volume":"33","author":"PK Kopparapu","year":"2013","unstructured":"Kopparapu PK, Boorjian SA, Robinson BD et al (2013) Expression of VEGF and its receptors VEGFR1\/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res 33:2381\u20132390","journal-title":"Anticancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3242-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T18:18:54Z","timestamp":1568917134000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3242-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["3242"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3242-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]}}}